The company has not filed an annual or quarterly report since its FY2020 10-K, filed Mar 16, 2021. Its latest SEC filing is a 15-12B from May 4, 2021.
10-K for FY2020, filed Mar 16, 2021
The sections below describe the company as of the FY2020 annual report.
Provides anesthesia services for patients undergoing endoscopic procedures and sells disposable hemorrhoid banding systems to gastroenterology practices.
10-K for FY2020, filed Mar 16, 2021
Anesthesia fees are billed to insurers, government programs or patients as procedures are completed. Physicians are billed for product sales when products ship.
10-K for FY2020, filed Mar 16, 2021Our anesthesia service revenues are derived from anesthesia procedures performed under our professional services agreements. The fees for…View ↗
Anesthesia services procedures for each patient qualify as a distinct service obligation, as they are provided simultaneously with other…View ↗
The Company recognizes revenue from product sales at the time the product is shipped, which is when title passes to the customer, and when…View ↗
Product sales contracts generally contain a single distinct performance obligation, but multiple performance obligations may exist when…View ↗
10-K for FY2020, filed Mar 16, 2021
FY2020 revenue by product or service ↗$106.2M
10-K for FY2020, filed Mar 16, 2021
$106.2M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Anesthesia Services
Usage-based
10-K for FY2020, filed Mar 16, 2021 |
92%
FY2017: 88%
|
Anesthesia Services, FY2020
$97.7M Sources
|
Usage-based |
|
Product
Sold outright
|
8.0%
FY2017: 12%
|
Product, FY2020
$8.5M Sources
|
Sold outright |
Gastroenterology practices buy the hemorrhoid-band system directly from CRH. Anesthesia services are provided for endoscopic procedures, with bills sent to insurers, government programs or patients.
10-K for FY2020, filed Mar 16, 2021
Not on paper. It lost $22.9M in FY2020, but brought in more cash than it spent: $36M of free cash flow.
10-K for FY2020, filed Mar 16, 2021
−$6.8MView ↗
10-K for FY2020, filed Mar 16, 2021
−$22.9MView ↗
10-K for FY2020, filed Mar 16, 2021
$36MView ↗
8-K, filed Apr 28, 2021
Vancouver, BC – April 22, 2021 – WELL Health Technologies Corp. (TSX: WELL) (“WELL”), a company focused on consolidating and modernizing…View ↗
8-K, filed Apr 5, 2021
This transaction will increase adjusted operating EBITDA attributable to shareholders, as CRH now owns 100% of LLAA. This transaction was…View ↗
8-K, filed Apr 1, 2021
VANCOUVER, BC, April 1, 2021 /CNW/ - CRH Medical Corporation ("CRH", or the "Company") (TSX: CRH) (NYSE MKT: CRHM) announces that it…View ↗
Grew. Revenue grew 12% in 3 years, from $95M in FY2017 to $106.2M in FY2020, about 4% a year.
Loading...
